ArticleBritish journal of cancer2006
Increased risk of second malignancies after in situ breast carcinoma in a population-based registry.
Article in British journal of cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Options for early breast cancer follow-up in primary and secondary care - a systematic review.BMC cancer · 2012Pooled it
- Article
- Bisphosphonate Use and Breast Cancer Risk among Women with Ductal CarcinomaCancer research · 2021Article
- Risk for Invasive Cancers in Women With Breast CancerFrontiers in oncology · 2021Article
- The Association between Cancer Screening and Cancer History among Korean Adults: The 2010-2012 Korea National Health and Nutrition Examination Survey.Korean journal of family medicine · 2019Article
- Reproductive and menopausal factors and risk of second primary breast cancer after in situ breast carcinoma.Cancer causes & control : CCC · 2019Article
- Article
- Family History and Risk of Second Primary Breast Cancer afterCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018Article
- Radiotherapy for ductal carcinoma in situ and risk of second non-breast cancers.Breast cancer research and treatment · 2017Article
- The impact of in situ breast cancer and family history on risk of subsequent breast cancer events and mortality - a population-based study from Sweden.Breast cancer research : BCR · 2016Article
- Value of Apparent Diffusion Coefficient Values in Differentiating Malignant and Benign Breast Lesions.Balkan medical journal · 2016Article
- Article
- Disease-free survival by treatment after a DCIS diagnosis in a population-based cohort study.Breast cancer research and treatment · 2013Article
- 'Second primary breast cancers following an initial diagnosis of cancer in one breast: a methodological issue'.British journal of cancer · 2008Article
- The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ.British journal of cancer · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among 1276 primary breast carcinoma in situ (BCIS) patients diagnosed in 1972-2002 in the Southern Netherlands, 11% developed a second cancer. Breast carcinoma in situ patients exhibited a two-fold increased risk of second cancer (standardised incidence ratios (SIR): 2.1, 95% confidence interval (CI): 1.7-2.5). The risk was highest for a second breast cancer (SIR: 3.4, 95% CI: 2.6-4.3; AER: 66 patients per 10,000 per year) followed by skin cancer (SIR: 1.7, 95% CI: 1.1-2.6; AER: 17 patients per 10,000 per year). The increased risk of second breast cancer was similar for the ipsilateral (SIR: 1.9, 95% CI: 1.3-2.7) and contralateral (SIR: 2.0, 95% CI: 1.4-2.8) breast. Risk of second cancer was independent of age at diagnosis, type of initial therapy, histologic type of BCIS and period of diagnosis. Standardised incidence ratios of second cancer after BCIS (SIR: 2.3, 95% CI: 1.8-2.8) resembled that after invasive breast cancer (SIR: 2.2, 95% CI: 2.1-2.4). Surveillance should be directed towards second (ipsi- and contra-lateral) breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.